Literature DB >> 12209700

Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors.

Ryota Tomoda1, Masashi Seto, Hideaki Tsumuki, Koji Iida, Takashi Yamazaki, Jun Sonoda, Akihiko Matsumine, Atsumasa Uchida.   

Abstract

BACKGROUND: Telomerase is a ribonucleoprotein enzyme that extends telomere specific repeats on the ends of chromosomes. Telomerase activity has been detected frequently in various types of human tumors and has been associated with cell immortality and oncogenesis. Human telomerase reverse transcriptase (hTERT), a telomerase catalytic subunit, reportedly regulates telomerase activity. Little is known about telomerase activity and hTERT mRNA expression in soft tissue tumors. The objective of this study was to clarify the correlation between these two parameters and clinical aggressiveness in soft tissue tumors.
METHODS: In 41 surgically resected soft tissue tumors, telomerase activity was measured by the fluorescence-based telomeric repeat-amplification protocol and hTERT mRNA expression was determined by real-time polymerase chain reaction.
RESULTS: Telomerase activity was detected in 52% of sarcomas and in none of the benign soft tissue tumors (P < 0.05). Telomerase activity was found in 77% of 13 locally recurrent sarcomas and in 89% of 9 sarcomas with distant metastasis. The frequency of the presence of telomerase activity in those tumors was significantly greater compared with the frequency of telomerase activity in the other sarcomas (P < 0.05 and P < 0.01, respectively). All telomerase positive sarcomas expressed hTERT mRNA. The mean level of hTERT mRNA expression in sarcomas was significantly greater compared with the mean hTERT mRNA expression level in benign tumors (P < 0.05) and in locally recurrent sarcomas compared with primary sarcomas (P < 0.001).
CONCLUSIONS: The results of the current study suggest that the detection of telomerase activity and the level of hTERT mRNA expression are useful markers for evaluating the clinical aggressiveness in soft tissue tumors. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209700     DOI: 10.1002/cncr.10793

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor.

Authors:  Xun Jin; Samuel Beck; Young-Woo Sohn; Jun-Kyum Kim; Sung-Hak Kim; Jinlong Yin; Xumin Pian; Sung-Chan Kim; Yun-Jaie Choi; Hyunggee Kim
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

2.  Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.

Authors:  Chunxia Liu; Bingcheng Li; Li Li; Haijun Zhang; Yunzhao Chen; Xiaobin Cui; Jianming Hu; Jingfang Jiang; Yan Qi; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

4.  Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo.

Authors:  Tong Xu; Yucheng Xu; Chun-Peng Liao; Roy Lau; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

5.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

6.  Influence of telomerase activity on bone and soft tissue tumors.

Authors:  Norifumi Umehara; Toshifumi Ozaki; Shinsuke Sugihara; Toshiyuki Kunisada; Yuki Morimoto; Akira Kawai; Keiichiro Nishida; Aki Yoshida; Takuro Murakami; Hajime Inoue
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

7.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

8.  Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas.

Authors:  Toshihiro Matsuo; Shoji Shimose; Tadahiko Kubo; Jun Fujimori; Yuji Yasunaga; Takashi Sugita; Mitsuo Ochi
Journal:  J Exp Clin Cancer Res       Date:  2012-01-16

9.  Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.

Authors:  B P Coe; W W Lockwood; L Girard; R Chari; C Macaulay; S Lam; A F Gazdar; J D Minna; W L Lam
Journal:  Br J Cancer       Date:  2006-05-16       Impact factor: 7.640

Review 10.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.